Our unique integrated offering combines specialized teams in medical strategy and excellence, evidence generation, clinical trials optimization, market access, patient engagement, medical analytics, and corporate and investor communications to provide scalable and targeted solutions and help you maximise your long-term success. View our new website here: www.medistrava.com #HealthcareInnovation #MedicalStrategy #MarketAccess #ClinicalTrials #PatientEngagement #Biotech #Pharma #CorporateCommunications #InvestorCommunications
MEDiSTRAVA, an Inizio Company
Pharmaceutical Manufacturing
London, England 2,718 followers
About us
TIME FOR TRANSFORMATION The real world is now a multi-dimensional universe of decision makers, evidence needs and healthcare systems requiring a connected, systematic and dynamic approach to medical and evidence planning, data dissemination, stakeholder engagement and education. The opportunity extends beyond traditional medical agency services to meet the growing and diversifying needs of medical affairs and finding integrated solutions in a fragmented and underserved market. We bring more than 20 years of experience in medical affairs with deep therapeutic expertise across oncology, specialised medicine and effecting change in chronic diseases. MEDiSTRAVA is part of Inizio Medical. Inizio is a strategic partner for health and life sciences with a full suite of medical, marketing, advisory and engagement services.
- Website
-
https://www.medistrava.com/
External link for MEDiSTRAVA, an Inizio Company
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- London, England
- Type
- Public Company
- Specialties
- Medical Affairs, Health Economics, Publications, Medical Education, Market Access, and Medical Congresses
Locations
-
Primary
26 Southampton Buildings
Holborn Gate, 6th Floor
London, England WC2A 1AN, GB
-
300 Vesey St
10th Floor New York
Manhattan, New York 10282, US
Employees at MEDiSTRAVA, an Inizio Company
Updates
-
Congratulations to our client Enara Bio on the close of its $32.5 million Series B financing, supported by a strong syndicate of strategic and venture investors. Read about Enara's fundraise and its strategy to build a pipeline of first-in-class TCR-based immunotherapies targeting novel Dark Antigens that could provide transformational clinical benefit to patients who are poorly served by today’s cancer treatments. 👉 https://lnkd.in/ejVHURzk #DarkAntigens #DarkGenome #Immunotherapy #SeriesB
We are thrilled to announce the closing of our $32.5 million Series B financing! The financing was co-led by two new strategic investors, Pfizer Ventures and M Ventures . All existing investors also joined the round – RA Capital Management, Samsara BioCapital and SV Health Investors – along with participation from the The Francis Crick Institute. The funding allows us to continue our pioneering research on Dark Antigens – a novel class of shared cancer antigens – and rapidly advance our pipeline of TCR-based immunotherapies against these exciting new targets. Follow the link for our full press release and to learn more about Dark Antigens: https://lnkd.in/ejVHURzk #DarkAntigens #DarkGenome #Immunotherapy #EnaraBio #Biotech
-
Are we ready for the next era of cancer care? It hinges on embedding the patient voice. Join us for Inizio's live webinar and explore how we can make this a reality. 🗓 October 8 | 3 PM (BST) 🎙 Featuring Alex Morton, SVP, Patient Engagement, Rachel Hatfield Managing Partner, Medical Strategy and Excellence, and Anna Capers from Inizio Evoke. 🔗 Register here: https://lnkd.in/eewCjPeM #Oncology #ReimagineHealth #Biopharma #Healthcare #InizioExpertsLive
-
🌟 Join us for an insightful session with our Managing Partner of Medical Strategy and Excellence, Rachel Hatfield. She’ll discuss the increasing recognition that prioritizing patients is essential for maximizing resources. 🗓 October 8th 🕛 15:00 BST 👉 Register now! https://lnkd.in/eewCjPeM
Efficient healthcare starts with patient-centered decisions. Rachel Hatfield, MEDiSTRAVA, an Inizio Company, emphasizes the growing recognition that putting patients first is critical to maximizing resources. Be part of this important conversation on the future of oncology in our upcoming webinar on October 8: https://lnkd.in/eewCjPeM #Oncology #ReimagineHealth #Biopharma #Healthcare #InizioExpertsLive
-
Proud to be part of a team that works strategically to help life science actors shape and amplify their stories. At MEDiSTRAVA, an Inizio Company, our deep dive experience in corporate, scientific, and medical communications ensures that our clients' messages reach the right stakeholders. 🌍 #StrategicCommunications #CorporateNarratives #GlobalReach #DeepExpertise #ProudToBePart
Together, we help you shape and amplify your corporate, scientific, and medical narratives to ensure that you reach relevant stakeholders globally, including media, investors, and corporates. View our new website here: www.medistrava.com #MedicalStrategy #MedicalExcellence #PatientEngagement #ClinicalTrialOptimization #MedicalAnalytics #MedicalInnovation #ValueAndEvidence #CorporateCommunications #InvestorCommunications
-
Together, we help you shape and amplify your corporate, scientific, and medical narratives to ensure that you reach relevant stakeholders globally, including media, investors, and corporates. View our new website here: www.medistrava.com #MedicalStrategy #MedicalExcellence #PatientEngagement #ClinicalTrialOptimization #MedicalAnalytics #MedicalInnovation #ValueAndEvidence #CorporateCommunications #InvestorCommunications
-
🌎 At MEDiSTRAVA, we believe all patient perspectives are important. We can help support pharmaceutical and biotech companies to improve clinical research design by engaging with patients. #NationalInclusionWeek is an opportunity to highlight the need for diversity and inclusion in clinical research. By encouraging diverse participation, clinical research can ensure that new therapies are effective for all patients. We must ensure that clinical trials are always designed and conducted in an inclusive way, embedding the patient voice throughout. You can learn more here: https://lnkd.in/deBDkkz. #ImpactMatters #NIW24
-
We're excited to be attending the 24th Annual Biotech in Europe Forum #Sachs_BEF next week in Basel, Switzerland. We look forward to attending a variety of keynote talks and panel sessions addressing the main challenges in biotech investment for 2024 as well as discussions around partnering and alliance management and prospects for 2025. Say hello to Sylvie Berrebi, Senior Consultant in our Strategic Communications team, to discuss how we can support you in creating and delivering bespoke communications programs designed to differentiate your business and help you stand out from the competition. About us: https://lnkd.in/egUZHrrd
-
Thank you to Mary Stuart for an insightful article in MedTech Strategist featuring our client Amber Therapeutics showcasing its groundbreaking efforts in developing an innovative device for mixed (urge and stress) urinary incontinence. This article highlights Amber’s recent success in raising $100 million to advance this critical solution, helping millions of women facing this life-altering condition. Subscribers to MedTech Strategist can read the article here: https://lnkd.in/dKXfMEiD #Innovation #Biotech #Oncology #Breakthroughs #AmberTherapeutics #MedTech #Leadership #Science #Healthcare
-
Our latest insight article from David Woods, VP Portfolio Lead, Medical Analytics & Innovation at MEDiSTRAVA explores the demystification of "omnichannel" and what this means for Medical Affairs. 💡 This piece offers insights on how we reframe Omnichannel into deeper, more meaningful scientific engagement. Read here: https://lnkd.in/eEQxtWis. #MedicalAffairs #Omnichannel #Engagement #Healthcare